Results 181 to 190 of about 213,470 (338)

Effect of Glucagon on Gastric Secretion in the Dog [PDF]

open access: bronze, 1960
Sonya Clarke   +2 more
openalex   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt   +18 more
wiley   +1 more source

Basal Plasma Glucagon Levels of Man* [PDF]

open access: bronze, 1967
Joseph E. Sokal, Ediz Z. Ezdinli
openalex   +1 more source

The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effects of baseline mitral regurgitation in the CABANA trial: randomization to catheter ablation versus drug therapy in patients with atrial fibrillation. AF, atrial fibrillation; CCS, Canadian Cardiovascular Society; MR, mitral regurgitation; NYHA, New York Heart Association; OR, odds ratio.
Sebastiaan Dhont   +8 more
wiley   +1 more source

Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few
Gianluigi Savarese   +28 more
wiley   +1 more source

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus

open access: yesТерапевтический архив, 2014
AIM. To study the secretion of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 2 (GLP-2) in response to a carbohydrate load in people with risk factors for type 2 diabetes mellitus (DM2) in ...
E A Shestakova   +3 more
doaj  

The Inductions of Tyrosine Aminotransferase by Glucagon and Hydrocortisone

open access: hybrid, 1967
Vilmos Csányi   +2 more
openalex   +1 more source

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease

open access: yesEuropean Journal of Heart Failure, EarlyView.
The value of uACR. CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; uACR, urine albumin‐to‐creatinine ratio. Abstract The high disease burden and bidirectional relationship of chronic kidney disease (CKD), heart failure (HF) and other cardiovascular disease (CVD) necessitate the need for early ...
Biykem Bozkurt   +2 more
wiley   +1 more source

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting. [PDF]

open access: yesMolecules
Ferreira B   +10 more
europepmc   +1 more source

Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction

open access: yesEuropean Journal of Heart Failure, EarlyView.
ABSTRACT Aims Overactivity of the sympathetic nervous system is a common underlying mechanism in development and progression of several heart failure with preserved ejection fraction (HFpEF) comorbidities. Decreasing renal sympathetic nerve activity using catheter‐based renal denervation (RDN) systems have shown efficacy in treating resistant ...
David J. Lefer   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy